Evidence-Based Guidelines on the Use of Intravenous Immune Globulin for Hematologic and Neurologic Conditions

In Canada, intravenous immune globulin (IVIG) use has increased by 115% over the past 7 to 8 years. Given this increased usage, Canadian Blood Services and the National Advisory Committee on Blood and Blood Products for Canada identified the need to develop and disseminate evidence-based guidelines...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion medicine reviews 2007-04, Vol.21 (2 Suppl 1), p.S3-S8
Main Authors: Robinson, Paula, Anderson, David, Brouwers, Melissa, Feasby, Thomas E, Hume, Heather
Format: Article
Language:English
Subjects:
Blood Banks
Canada
Drug Utilization
Evidence-Based Medicine
Hematologic Diseases - drug therapy
Hematology, Oncology and Palliative Medicine
Humans
Immunoglobulins, Intravenous - therapeutic use
Nervous System Diseases - drug therapy
Practice Guidelines as Topic
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In Canada, intravenous immune globulin (IVIG) use has increased by 115% over the past 7 to 8 years. Given this increased usage, Canadian Blood Services and the National Advisory Committee on Blood and Blood Products for Canada identified the need to develop and disseminate evidence-based guidelines to facilitate appropriate IVIG use. As a result, guidelines for IVIG use in hematologic and neurologic conditions have been developed and are published in this supplement of Transfusion Medicine Reviews . This commentary provides a brief description of the process used to develop these guidelines and includes a summary of the recommendations for IVIG use in the various conditions evaluated.
ISSN:0887-7963
1532-9496
DOI:10.1016/j.tmrv.2007.01.004